Change region


Midamox™ (imidacloprid + moxidectin) Topical Solution

Midamox (imidacloprid + moxidectin) logo


Introducing Midamox™ (imidacloprid + moxidectin) topical solution from Norbrook®. Bioequivalent to Advantage Multi® and made with the only combination of active ingredients approved by the FDA to kill circulating heartworm microfilariae in dogs, Midamox is an effective, affordable choice for protecting pets against heartworm disease, treating flea infestations and treating and controlling several other parasites.


Midamox™ offers a range of dosage volumes or sizes to accommodate various weights of cats and dogs.

CAUTION: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.

Dogs: WARNING: DO NOT ADMINISTER THIS PRODUCT ORALLY. For the first 30 minutes after application, ensure that dogs cannot lick the product from application sites on themselves or other treated animals. (See Contraindications and Adverse Reactions for more information.)

Cats: WARNING: Do not use on sick, debilitated or underweight cats. (See Contraindications and Adverse Reactions for more information.) Do not use in cats less than 9 weeks of age.

PRECAUTIONS: Avoid oral ingestion.

HUMAN WARNINGS: Children should not come in contact with application sites for 2 hours after application.

© 2022 Norbrook Laboratories Limited. The Norbrook logo is a registered trademark and Midamox is a trademark of Norbrook Laboratories Limited. Advantage Multi is a registered trademark of Elanco or its affiliates.

To learn more, contact us at 866-591-5777. To place an order, contact your veterinarian or distributor. 


Please note: Product information presented on this website is intended only as a brief summary of Norbrook products for your convenience. Not all products or indications are licensed in every country and may be subject to further local variations. For specific product information you should always consult a healthcare professional from your region or visit the local government agency website for the most up to date information. Please see our terms and conditions for further information.